Hepatitis C Infection Among Dialysis Patients: A Comparison Between Patients on Maintenance Haemodialysis and Continuous Ambulatory Peritoneal Dialysis

Chan, Tak Mao; Lok, Anna S.; Cheng, Ignatius K.P.

doi:10.1093/ndt/6.12.944

Cited by 62 publications

(29 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The marked difference in prevalence of anti-HCV among patients receiving CAPD and HD is related to more frequent transfusion requirements of patients receiving HD. Risk of HCV infection is significantly increased in those who receive more than 5 U of blood [24]. In our study, all of the patients who were anti-HCV positive had a history of multiple transfusions.…”

Section: Discussionmentioning

confidence: 63%

“…Acute HCV infection detected in patients undergoing chronic HD in developed countries, after elimination of posttransfusion HCV infection, also supports HCV transmission by nosocomial routes [24,[26][27][28][29].…”

Section: Discussionmentioning

confidence: 78%

“…The anti-HCV positivity of persons undergoing HD ranges from 10.6% to 76% for different countries around the world [21][22][23]. In Hong Kong, the rate is 16.4% [24,25].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Distribution of HCV Genotypes in Patients with End-Stage Renal Disease According to Type of Dialysis Treatment

et al. 2006

View full text Add to dashboard Cite

The objective of this study was to investigate the effects of types of dialysis treatments on hepatitis C virus infection and the epidemiologic properties of hepatitis C virus (HCV) infection at three Baskent University hospitals, in Ankara, Adana, and Izmir, Turkey, in 655, 326, and 118 patients with end-stage renal disease, respectively. One hundred thirty patients with HCV viremia among 271 patients with end-stage renal disease seropositive for HCV were included in this cross-sectional study. HCV RNA-positive patients were classified according to the renal replacement therapies (hemodialysis or continuous ambulatory peritoneal dialysis), and viral load, transaminase levels, and distribution of genotypes were compared between these subgroups. In the continuous ambulatory peritoneal dialysis group, 26 of 165 patients (16%) were serum anti-HCV positive, and 11 of 26 patients (42%) were serum HCV RNA positive. Twenty-six percent of the patients undergoing hemodialysis were anti-HCV positive, and 49% were HCV RNA positive. The prevalence of genotype 1b was 68% and 73% for patients in the continuous ambulatory peritoneal dialysis and hemodialysis groups, respectively. No significant differences were found between the genotype 1b and the non-1b groups or between different dialysis types with regard to age and sex and serum aspartate transaminase, alanine aminotransferase, and HCV RNA levels. We conclude that HCV seropositivity may differ between different types of dialysis treatments, although viral load and genotypes may be similar in persons with end-stage renal disease and those without.

show abstract

Section: Discussionmentioning

confidence: 63%

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Distribution of HCV Genotypes in Patients with End-Stage Renal Disease According to Type of Dialysis Treatment

et al. 2006

View full text Add to dashboard Cite

show abstract

“…74-76], suggest that HCV may be transmitted within the HD environment. The lower prevalence of HCV infection in patients treated with ambulatory peritoneal dialysis [77] reinforce this hypothesis.…”

Section: Prevalence and Incidence O F Hcv Infection Among Iid Patientsmentioning

confidence: 78%

Nosocomial Hepatitis C in Dialysis Units

Sampietro

Badalamenti

Graziani

1996

Nephron

View full text Add to dashboard Cite

“…In addition, PD provides flexible schedules (unlike fixed HD shifts), thus bestowing opportunities to work, travel, and par- ticipate in daytime activities for patients. PD being needleless, alleviates the anxiety experienced by HD patients from needle sticks, helps to preserve arteriovenous access sites for future HD, and minimizes risks of acquiring blood-borne infections like hepatitis C. 12,13 In addition, PD facilitates preservation of residual renal function (RRF) better than HD. 14 PD may also contribute to superior allograft function in the postoperative period following a kidney transplant.…”

Section: Pros and Cons Of Peritoneal Dialysismentioning

confidence: 99%

Peritoneal Dialysis: A Primary Care Perspective

Saxena¹,

West²

2006

The Journal of the American Board of Family Medicine

View full text Add to dashboard Cite

As the population of chronic kidney disease (CKD) and end-stage renal disease (ESRD) grows at an alarming rate, primary care physicians will increasingly be involved in the management of these patients. Early recognition of CKD and timely referral to a nephrologist when glomerular filtration rate approaches 30 mL/min/1.73 m 2 is extremely important to improve ESRD outcome and appropriate selection of dialysis modality. Peritoneal dialysis (PD) remains a viable treatment option for ESRD patients. PD is less expensive dialysis modality and may provide a survival advantages over hemodialysis in first 2 to 4 years of treatment. Preserving residual renal function (RRF) is of paramount importance to prolong the survival outcomes in PD patients. Thus preservation of RRF is an important goal in the management of PD patients. Every effort should be made to avoid nephrotoxic drugs like aminoglycosides and nonsteroidal anti-inflammatory drugs, and limit the use of radiocontrast agents in PD patients with RRF. Judicious use of prophylactic antibiotics to prevent peritonitis would further help to reduce morbidity from PD. Protecting peritoneal membrane from long-term toxic and metabolic effects of the conventional glucose-based solutions is another objective to further improve PD outcome. Development of new, more biocompatible PD solutions holds promise for the future. One such solution, icodextrin, is now approved for use in the United States. Although extremely safe to use, it is associated with unique metabolic effects that may concern primary care physicians. They include false elevation of blood glucose, a reversible increase in serum alkaline phosphatase and a false decline in serum amylase. Monitoring of glycemia by assays that use glucose dehydrogenase pyrroloquinoline quinone enzymes should be avoided and serum amylase alone should not be relied on in diagnosing pancreatitis in patients on icodextrin. (

show abstract

Hepatitis C Infection Among Dialysis Patients: A Comparison Between Patients on Maintenance Haemodialysis and Continuous Ambulatory Peritoneal Dialysis

Cited by 62 publications

References 0 publications

Distribution of HCV Genotypes in Patients with End-Stage Renal Disease According to Type of Dialysis Treatment

Distribution of HCV Genotypes in Patients with End-Stage Renal Disease According to Type of Dialysis Treatment

Nosocomial Hepatitis C in Dialysis Units

Peritoneal Dialysis: A Primary Care Perspective

Contact Info

Product

Resources

About